Synergistic effects of rapamycin and EGFR TKIs have been observed in several in vitro systems, including glioblastoma multiforme, prostate cancer, pancreatic cancer, squamous cell carcinoma, renal cell carcinoma, leukemia, cervical carcinoma, and NSCLC cell lines, as well as in some xenografts [62–67]. Here, EGFR is linked to familial pancreatic carcinoma.